Fig. 7. The paclitaxel/S63845 combination inhibits the growth of xenografts bearing BAK/MCL1 complexes.
a Diagram of this assay. b Kaplan–Meier survival curve of OVCAR8 inoculated mice. Each group was treated with or without paclitaxel (1.5 mg/kg) and/or S63845 (15 mg/kg) as indicated in panel (a). COX proportional hazards model for paclitaxel + S63845 vs. control was χ2 = 9.897 (p = 0.002), while no significance was observed for paclitaxel or S63845 vs. control (n = 10). c, d Tumor volume (c) and weight (d) of each group (n ≥ 4 mice in each group at the start of treatment, mean ± S.E.M.) observed in OVCAR8 tumor-bearing mice after the start of treatment with vehicle (control), S63845, paclitaxel, and paclitaxel + S63845. e Tumors from the control group, S63845 group, paclitaxel group, and combination group were obtained for comparison from OVCAR8 tumor-bearing mice at day 21. f, g Cleaved-caspase 3 by IHC using tumor tissue from OVCAR8 tumor-bearing mice at day 21 (f) and the intensity profiling of DAB stained image were calculated using ImageJ program (g). All images are captured at 20× magnification. (n = 4, mean ± S.D.) Scale bar in panel f 200 μm. Statistical significance in panels c, d, and g was determined by a two-sided unpaired Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.